Suppr超能文献

通过小鼠玫瑰花结试验鉴别慢性淋巴细胞白血病与其他“高分化至中分化”淋巴增殖性疾病。

Differentiation of chronic lymphocytic leukemia from other "well to intermediate differentiated" lymphoproliferative disorders by the mouse rosette assay.

作者信息

Hicks M J, Grogan T M, Fielder K, Spier C M

出版信息

Diagn Immunol. 1986;4(1):31-6.

PMID:3456864
Abstract

The usefulness of the mouse rosette (MR) assay in differentiating among various "well to intermediate differentiated" lymphoproliferative disorders (LPD) is presented. Thirty patients with a suspected LPD were studied. By standard histologic, cytologic, immunologic (surface immunoglobulin and monoclonal antibody markers), and clinical criteria, the following diagnoses (independent of MR data) were made: chronic lymphocytic leukemia (CLL) (n = 12), CLL in transformation (n = 2), well-differentiated lymphocytic lymphoma (WDLL) (n = 5), intermediate-differentiated lymphoma (IDL) (n = 2), hairy cell leukemia (HCL) (n = 3), prolymphocytic leukemic (PLL) (n = 1), poorly differentiated lymphocytic lymphoma (PDL) (n = 1), and no disease or reactive lymphocytosis (n = 4). There were 11 B-CLL cases and one T-CLL case. The percent of MR in all cases of B-CLL ranged from 26 to 76% (m = 62%); 10/11 cases had greater than or equal to 50% MR. The case with 26% MR was atypical in that it occurred in a 26-year-old patient. The percent of MR ranged from 0 to 42% (m = 16%) in the cases of well to intermediate differentiated lymphomas. Similar to previous reports intermediate proportions of MR were seen in HCL (12-41%); and low values were seen in PDL (4%) and PLL (4%). In summary, the MR assay may be a useful tool for differentiating CLL from other well to intermediate differentiated LPD involving the peripheral blood. Also, since the MR receptor is normally found only on functionally immature cells, this differential mouse rosetting capability suggests that CLL arises from a less mature cell than WDLL or IDL.

摘要

本文介绍了小鼠玫瑰花结(MR)试验在鉴别各种“高分化至中分化”淋巴细胞增殖性疾病(LPD)中的作用。对30例疑似LPD患者进行了研究。根据标准的组织学、细胞学、免疫学(表面免疫球蛋白和单克隆抗体标志物)及临床标准,做出了以下诊断(与MR数据无关):慢性淋巴细胞白血病(CLL)(n = 12)、转化型CLL(n = 2)、高分化淋巴细胞淋巴瘤(WDLL)(n = 5)、中分化淋巴瘤(IDL)(n = 2)、毛细胞白血病(HCL)(n = 3)、原淋巴细胞白血病(PLL)(n = 1)、低分化淋巴细胞淋巴瘤(PDL)(n = 1)以及无疾病或反应性淋巴细胞增多症(n = 4)。其中有11例B - CLL病例和1例T - CLL病例。所有B - CLL病例的MR百分比范围为26%至76%(平均值 = 62%);11例中有10例MR≥50%。MR为26%的病例不典型,该病例发生在一名26岁患者身上。高分化至中分化淋巴瘤病例的MR百分比范围为0至42%(平均值 = 16%)。与先前报道相似,HCL中可见中等比例的MR(12% - 41%);PDL(4%)和PLL(4%)中MR值较低。总之,MR试验可能是一种有用的工具,可用于鉴别CLL与其他累及外周血的高分化至中分化LPD。此外,由于MR受体通常仅在功能不成熟的细胞上发现,这种不同的小鼠玫瑰花结形成能力表明CLL起源于比WDLL或IDL更不成熟的细胞。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验